Navigation Links
Integra Epilepsy Gates/Dunn Electrodes

ProductsIntegra Epilepsy Gates/Dunn Electrodes
Company Integra LifeSciences Corporation
Item Integra Epilepsy Gates/Dunn Electrodes
Features 
Description Designed in collaboration with Drs. John R. Gates and Mary E. Dunn at the Minnesota Epilepsy Group, Gates/Dunn electrodes are designed for reliability, safety and ease of use. For cortical strip and grid electrodes, platinum contacts are mounted flush with the electrode surface, are individually numbered and have larger exposures. Strip and depth electrodes are fitted with a gold plated mini-PC board connector; larger grids incorporate a single gold-plated Flex Connector. Electrode leads are extra long and durable to ensure reliable recording. Strip and grid electrodes have standard 1 cm spacing; the platinum depth electrodes have 1.5 cm spacing.
Info Integra LifeSciences Corporation
Customer Service: (800) 654-2873
Web site: http://www.integra-ls.com/

Related medicine products :

1. ADVIA IMS 800i Integrated Modular System
2. Dimension RxL Max™ Integrated Chemistry System 50/60HZ
3. Dimension RxL Max™ Integrated Chemistry System
4. Dimension Xpand Plus Integrated Chemistry System
5. Architect ci8200 Integrated System
6. Cobas Integra 400 plus
7. Cobas Integra 800
8. Integrated Shoulder System
9. MSP-3 Special Procedure wrap-around with Integrated Wide Belt
10. Integra Epilepsy Grid Electrodes
11. Integra Epilepsy Flex Connector Grid Electrodes
Reservoir, 1 Well, 10/Box
For use with 8 channel pipets.
..., manually adjustable dispensing head, and disposa...ings unparalleled flexibility and cost-efficiency ...strument of its kind to offer fast dispensing of f...L). It also offers the added benefit of being able...
...ted non-contact dispensing technique that couples ...e and stage stepper motor. synQUAD dispenses a pre...s, plates, or membranes. At 100 nL dispense volume... than 10%. An 8-channel synQUAD system dispenses 1...
Medicine Products:
(Date:8/27/2008)... The American Society for Therapeutic Radiology an...ist Audrey Evans, M.D., as its 2008 honorary membe...Ceremony held Tuesday, September 23, at 10:00 a.m....r. Evans has been on the forefront of the treatmen...as one of the co-founders of the original Ronald M...
(Date:8/27/2008)...inding could lead to new drugs in fight against ob... (HealthDay News) -- A chemical produced in the br... likelihood of becoming obese, according to a new ...a group of 33 people who had WAGR syndrome, a gene...illion people. WAGR is an acronym for the symptoms...
(Date:8/27/2008)...dding Velcade to standard drug therapy prolonged s... 27 (HealthDay News) -- Patients with multiple mye... lived longer and better by adding the drug Velcad...he finding could make multiple myeloma, a cancer o...a lethal disease. And it would be particularly val...
(Date:8/27/2008)...tudy also uncovers risks associated with treating ...DAY, Aug. 27 (HealthDay News) -- Scientists from t...st gene directly associated with the onset of seve... age-related macular degeneration that currently t...ericans. , The discovery, based on work with bo...
Breaking Medicine News(10 mins):Health News:ASTRO selects pediatric oncologist as 2008 honorary member 2Health News:Low Levels of Brain Chemical May Control Appetite 2Health News:Combination Therapy Helps to Combat Myeloma 2Health News:Combination Therapy Helps to Combat Myeloma 3Health News:Gene Linked to 'Dry' Macular Degeneration 2Health News:Gene Linked to 'Dry' Macular Degeneration 3
... by a deterioration of the retina, is the number o... vitamin supplement could significantly // reduce ...ated macular degeneration, or AMD, finds a new stu...s conducted a large study to see if a combination ...
...t has existed for centuries, doctors say. But only... headaches," or CDH, defined as migraines or neck-...resent 15 or more days each month. Some might thi... skip school. But young people such as Rachel Gohm...
...birth of their child is a joyous experience. But i...ve a detrimental impact on the woman. Researchers ...the impact of an //operative delivery in the secon...egnant women need better preparation and understan...
Other Medicine News:Health News:Finding relief from Excruciating Headaches a challenge 2Health News:Finding relief from Excruciating Headaches a challenge 3
(Date:8/26/2008)...RN, Mass., Aug. 26 /- Cambridge Resea...lease of the Maestro(TM) EX In,Vivo Imaging System...rt,FLEX technology and becomes the entry-level ins...., (Photo: http://www.newscom.com/cgi-bin/prnh/2...significant advancement of CRi,s unique,solid-stat...
(Date:8/26/2008)...accine - Coupled with Innovative Manufacturing - H...l Pandemic Preparedness, ROCKVILLE, Md., Aug. 26 ...NVAX ) announced today favorable results from the ...al of its pandemic influenza virus-like,particle (...t contain an,adjuvant, induced robust neutralizing...
(Date:8/25/2008)...iscovers Stem Cells Found in Menstrual Blood May O...s for Time-Pressed Women, OLDSMAR, Fla., Aug. 25 ...Yet most women would agree that there never seems ... woman spends on doing something just,for herself ...s in others.,This reality has led many women in ne...
(Date:8/25/2008)...ESLEY HILLS, Mass., Aug. 25 /- Joseph...sets of Spherics, Inc. ("Spherics") for,the benefi...tical,intellectual property will be sold at a seal...n extended release formulation of Levodopa-Carbido... Parkinson,s disease, with global,sales estimated ...
Breaking Medicine Technology:CRi Announces New Maestro(TM) EX In Vivo Imaging System with Improved Performance and an Affordable Price 2Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program 2Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program 3Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program 4Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program 5Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program 6Going Beyond 'Spa Day': Giving Women the Opportunity to Do Something Proactive Which May Lead to Long Term Health Benefits 2Spherics, Inc. Offers Extended Release Formulation for Sustained and Stable Levodopa Levels 2STEN Corp Reports 2008 Second Quarter Revenue of 244 3 Million and Improved Results From Operations 19400 1STEN Corp Reports 2008 Second Quarter Revenue of 244 3 Million and Improved Results From Operations 19400 2STEN Corp Reports 2008 Second Quarter Revenue of 244 3 Million and Improved Results From Operations 19400 3STEN Corp Reports 2008 Second Quarter Revenue of 244 3 Million and Improved Results From Operations 19400 4STEN Corp Reports 2008 Second Quarter Revenue of 244 3 Million and Improved Results From Operations 19400 5Cool new treatment for hot flashes in breast cancer survivors 19396 1Cool new treatment for hot flashes in breast cancer survivors 19396 2Cool new treatment for hot flashes in breast cancer survivors 19396 3NARALS CHOICE 3A Is Anyone Surprised About Out of the Mainstream NARALs Choice of Barack Obama for President 3F 19392 1NARALS CHOICE 3A Is Anyone Surprised About Out of the Mainstream NARALs Choice of Barack Obama for President 3F 19392 2NARALS CHOICE 3A Is Anyone Surprised About Out of the Mainstream NARALs Choice of Barack Obama for President 3F 19392 3Vaxgen Files 10 Q for First Quarter With SEC Provides Future Burn Rate Guidance 5412 1Vaxgen Files 10 Q for First Quarter With SEC Provides Future Burn Rate Guidance 5412 2Vaxgen Files 10 Q for First Quarter With SEC Provides Future Burn Rate Guidance 5412 3
...AMBRIDGE, England, 4th May 2007 - CeNeS Pharmaceut...aceutical company, notes,the publication of an ind... ,Synapse,* on its Phase II NMDA antagonist, CNS 5...reatment for neuropathic,pain. The independent stu...taken with CNS 5161. , In the study reported in ,S...
...NSAS CITY, Mo.--(BUSINESS WIRE)--May 4, 2007 - New... that a combination of,COPAXONE(R) (glatiramer ace...ocycline reduced T1 Gadolinium (Gd)-enhancing lesi...s with active,relapsing-remitting multiple scleros...ng (MRI), compared to those receiving,COPAXONE(R) ...
Other Medicine Technology:Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 2Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5